Moderna
$128.409876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$128.40
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$17.85 (+16.35%) Today
+$1.37 (+1.08%) As of 5:00 PM EST after-hours
Why Robinhood?
You can buy or sell Moderna and other stocks, options, and ETFs commission-free!
About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA. The listed name for MRNA is Moderna, Inc. Common Stock.
CEO
Stéphane Bancel
Employees
830
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
50.27B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
26.25M
High Today
$130.06
Low Today
$114.86
Open Price
$115.12
Volume
43.44M
52 Week High
$130.06
52 Week Low
$17.68
Collections
Digestible Financial News
Jack Kramer & Nick Martell
Managing Editors of News & Snacks at Robinhood Financial LLC
MRNA News
CNBC7h
UK secures 2 million more doses of Moderna's Covid vaccine
Researchers work in a lab run by Moderna Inc, who said November 16, 2020 that its experimental vaccine was 94.5% effective in preventing COVID-19 based on inter
Analyst Ratings
80%
of 15 ratings
Buy
80%
Hold
13%
Sell
7%
MRNA Earnings
-$0.59
-$0.39
-$0.20
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 24, Pre-Market
